Revolutionizing Emergency Room Care: suPARnostic® Quick Triage Shortens Patient Stay and Enhances Discharge Rates

Mon Sep 10 2018

At the 12th European Congress of Emergency Medicine held in Glasgow, the remarkable findings of the TRIAGE III study were unveiled, highlighting the transformative potential of suPARnostic® Quick Triage in emergency departments. This innovative approach slashed patient Emergency Department (ED) stays by 6.5 hours on average and notably increased the rate of patients discharged within 24 hours.

Comparing suPARnostic® Quick Triage to conventional triage systems, the cluster-randomized TRIAGE III study encompassed 16,801 patients. Among them, 7,905 had their suPAR protein levels swiftly assessed, aiding ED medical teams in making informed decisions. Notably, suPAR outshone other biomarkers like age, CRP, and albumin in prognostic accuracy for short-term mortality prediction. Over a 362-day follow-up, mortality rates were comparable between the suPAR and control groups.

Patients benefiting from suPARnostic® Quick Triage enjoyed significantly shorter ED stays (mean reduction of 6.5 hours) and a substantially higher rate of discharges within 24 hours, underscoring the system’s efficacy (both statistically significant at p<0.05).

Dr. Schultz, the study’s lead, emphasized that low suPAR levels can pinpoint patients with favorable prognoses and minimal short-term mortality risk. This is particularly vital for time-sensitive emergency departments managing high patient volumes. By expediting the discharge process for low-risk patients who might not necessitate hospitalization, both individuals requiring medical attention and those suitable for safe discharge stand to benefit.

In essence, these findings underscore how suPAR measurements in EDs empower healthcare providers to make swifter discharge decisions, without impacting mortality rates, consequently optimizing resource utilization and conserving valuable time within healthcare systems. This breakthrough not only streamlines patient care but also holds the potential to revolutionize emergency medical practices on a broader scale.

Data from the TRIAGE III study were presented by investigator Martin Schultz, MD. Please find the abstract text here;

The TRIAGE III trial was a cluster-randomized interventional trial conducted at emergency departments at Herlev Hospital and Bispebjerg Hospital in the Capital Region of Denmark. The inclusion period was from January through June of 2016 and consisted of twelve cluster-periods of 3-weeks alternating between intervention and control and a subsequent follow-up of ten months.The study has been registered in clinicaltrials.gov, NCT02643459

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates